U.S. Markets close in 4 hrs 41 mins

ResMed Inc. (RSMDF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
28.160.00 (0.00%)
As of 11:33AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close28.16
BidN/A x N/A
AskN/A x N/A
Day's Range28.16 - 28.16
52 Week Range17.50 - 28.16
Avg. Volume42
Market Cap43.65B
Beta (5Y Monthly)0.30
PE Ratio (TTM)36.00
EPS (TTM)0.78
Earnings DateN/A
Forward Dividend & Yield0.16 (0.59%)
Ex-Dividend DateMay 12, 2021
1y Target Est11.49
  • Zacks

    ResMed (RMD)-Backed Landmark ALASKA Study Favors PAP Therapy

    A late-breaking abstract from ResMed (RMD) supported landmark ALASKA study reported that treatment with PAP therapy improves the likelihood of longevity in sleep apnea patients

  • GlobeNewswire

    ResMed Announces Participation in the Bank of America Global Healthcare Conference

    SAN DIEGO, Sept. 08, 2021 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced Rob Douglas, president and chief operating officer, will participate in a virtual fireside chat at the Bank of America Global Healthcare Conference on Wednesday, September 15, 2021, beginning at approximately 5:35 p.m. (British Summer Time) via video webcast. More information about this event, including access to the live webcast, may be accessed by visiting https://investor.resmed.com. The webcast replay

  • GlobeNewswire

    People with Sleep Apnea Live Longer on CPAP in Large, Late-Breaking ResMed-Supported ALASKA Study Presented at ERS

    Continued PAP use linked to 39% higher chance of survival over a 3-year periodLYON, France, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Using PAP (positive airway pressure) therapy as directed can significantly increase sleep apnea patients’ chances of living longer, according to a late-breaking abstract presented today at the virtual European Respiratory Society (ERS) International Congress 2021 and supported by ResMed (NYSE: RMD, ASX: RMD). The landmark ALASKA study, “CPAP Termination and All-Cause Mor